Search for content, post, videos

AstraZeneca’s Calquence granted first regulatory approval in China

Dave Fredrickson
Calquence, a next generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been conditionally approved in China for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. This is the first approved indication for Calquence in Chi
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.